Inspire Medical Systems' stock plunged 7.65% in after-hours trading on Wednesday, following the release of its fourth-quarter and full-year 2025 financial results.
The medical technology company reported strong quarterly performance with Q4 revenue of $269.1 million, beating analyst estimates of $265.7 million and representing 12% year-over-year growth. Net income per diluted share surged 182% to $4.66 for the quarter, while adjusted EPS came in at $1.65.
Despite these positive results, investors reacted negatively to the company's revised 2026 outlook. Inspire Medical Systems now expects 2026 revenue between $950 million and $1 billion, representing growth of just 4% to 10%. The company also provided adjusted EPS guidance of $1.85 to $2.35 for 2026, with an adjusted operating margin projected between 6% and 8%.